Hi Bob. Some follow up questions about your VPHM forecast:
I think they will do $1 pretax in 2005 so .65 to you.
Does that pretax number include: a) milestone payments under the royalty arrangement? b) derivative income (loss)?
I'm having a hard time coming up with a decent valuation target here because I'm not sure how I should treat the milestone payments. They obviously have some value, because they can be used to pay off debt, fund R&D, etc....but they will end at some point in the future. You felt that the sum of those payments for pleconaril could be as high as $65MM. Has the company discussed the timetable for potential FDA approval on this? IF approved and all milestone payments are received, then all subsequent revs would drop down to the % of sales of the drug (i.e. royalties?).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.